Interferon-β-1a (Avonex) 30 mcg and 60 mcg are equally effective in patients with relapsing multiple sclerosis:: results from the Cyprus study site of the European IFNβ-1a Dose Comparison Study

被引：0
作者：
Kkolou, E [1 ]
Papacostas, S [1 ]
Kyriallis, K [1 ]
Toufexis, J [1 ]
Pantzaris, M [1 ]
机构：
[1] Cyprus Inst Neurol & Genet, Nicosia, Cyprus
来源：
MULTIPLE SCLEROSIS | 2004年 / 10卷 / 7032期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S243 / S243
页数：1
相关论文
共 50 条
  • [21] Safety of adult doses of subcutaneous interferon-β-1a in children and adolescents with multiple sclerosis: results of the REPLAY study
    Ghezzi, A.
    Pohl, D.
    Banwell, B.
    Krupp, L. B.
    Boyko, A.
    Meinel, M.
    Lehr, L.
    Moraga, M. Stam
    Tenembaum, S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 74 - 75
  • [22] A preliminary metabolomic study of patients with multiple sclerosis treated with interferon β 1a
    Cocco, E.
    Lorefice, L.
    Murgia, F.
    Barberini, L.
    Frau, J.
    Fenu, G.
    Coghe, G.
    Melis, M.
    Murru, M. R.
    Murru, R.
    Poddighe, S.
    Atzori, L.
    Marrosu, M. G.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 264 - 264
  • [23] Disability and impact profile in multiple sclerosis patients treated with high-dose interferon-β 1a
    Schluep, M
    Bogousslavsky, J
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S252 - S252
  • [24] ASA Study -: combination of interferon-β 1a, azathioprine and oral prednisone in remitting multiple sclerosis
    Horakova, D
    Havrdova, E
    Krasensky, J
    Meluzinova, E
    Dolezal, O
    Vaneckova, M
    Seidl, Z
    Svobodnik, A
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S262 - S263
  • [25] Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study
    Bayas, Antonios
    Ouallet, Jean Christophe
    Kallmann, Boris
    Hupperts, Raymond
    Fulda, Ulrich
    Marhardt, Kurt
    EXPERT OPINION ON DRUG DELIVERY, 2015, 12 (08) : 1239 - 1250
  • [26] Subcutaneous interferon-β-1a in paediatric patients with multiple sclerosis: regional outcomes in an international retrospective study (REPLAY)
    Krupp, L. B.
    Pohl, D.
    Ghezzi, A.
    Boyko, A.
    Tenembaum, S.
    Meinel, M.
    Moraga, M. Stam
    McIlroy, C.
    Lehr, L.
    Banwell, B.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 298 - 298
  • [27] Adherence to self-administering interferon-β1a using RebiSmart® device in Mexican patients with relapsing multiple sclerosis
    Sauri-Suarez, Sergio
    Quinones-Aguilar, Sandra
    Contreras-Marin, Arturo
    Omar Ramiro-Guerrero, Erik
    Zuniga-Garcia, David
    Salinas-Vazquez, Leticia
    Llamas-Lopez, Leonardo
    Leon-Jimenez, Carolina
    Garcia-Martell, Adriana
    Gonzalez-Hernandez, Iliana
    Chiquete, Erwin
    Garcia, Silvia
    PLOS ONE, 2020, 15 (04):
  • [28] A randomized, controlled trial of interferon-β-1a (Avonex®) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]
    Mark C Genovese
    Eliza F Chakravarty
    Eswar Krishnan
    Larry W Moreland
    Arthritis Res Ther, 6
  • [29] The PRISMS study. Interferon-β 1a (Rebif) in intermittent multiple sclerosis [Die PRISMS-studie. Interferon-β 1a (Rebif®) bei schubformiger multipler sklerose]
    Hartung H.-P.
    Flachenecker P.
    Weilbach F.X.
    Rieckmann P.
    Der Nervenarzt, 1999, 70 (2) : 182 - 185
  • [30] 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon β-1a:: results of a preliminary study
    Sarchielli, P
    Presciutti, O
    Tarducci, R
    Gobbi, G
    Alberti, A
    Pelliccioli, GP
    Orlacchio, A
    Gallai, V
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (02) : 204 - 212
12345